Differential Effects of Histone Deacetylase Inhibitors in Tumor and Normal Cells—What Is the Toxicological Relevance?
- 1 January 2005
- journal article
- review article
- Published by Informa UK Limited in Critical Reviews in Toxicology
- Vol. 35 (4), 363-378
- https://doi.org/10.1080/10408440590935639
Abstract
Histone deacetylase (HDAC) inhibitors target key steps of tumor development: They inhibit proliferation, induce differentiation and/or apoptosis, and exhibit potent antimetastatic and antiangiogenic properties in transformed cells in vitro and in vivo. Preliminary studies in animal models have revealed a relatively high tumor selectivity of HDAC inhibitors, strenghtening their promising potential in cancer chemotherapy. Until now, preclinical in vitro research has almost exclusively been performed in cancer cell lines and oncogene-transformed cells. However, as cell proliferation and apoptosis are essential for normal tissue and organ homeostasis, it is important to investigate how HDAC inhibitors influence the regulation of and interplay between proliferation, differentiation, and apoptosis in primary cells as well. This review highlights the discrepancies in molecular events triggered by trichostatin A, the reference compound of hydroxamic acid-containing HDAC inhibitors, in hepatoma cells and primary hepatocytes (which are key targets for drug-induced toxicity). The implications of these differential outcomes in both cell types are discussed with respect to both toxicology and drug development. In view of the future use of HDAC inhibitors as cytostatic drugs, it is highly recommended to include both tumor cells and their healthy counterparts in preclinical developmental studies. Screening the toxicological properties of compounds early in their development process, using a battery of different cell types, will enable researchers to discard those compounds bearing undesirable adverse activity before entering into expensive clinical trials. This will not only reduce the risk for harmful exposure of patients but also save time and money.Keywords
This publication has 176 references indexed in Scilit:
- Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentialsBiochemical and Biophysical Research Communications, 2004
- Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activityBiochemical and Biophysical Research Communications, 2002
- Cyclin kinase inhibitor p21 potentiates bile acid-induced apoptosis in hepatocytes that is dependent on p53Hepatology, 2002
- Phylogenetic Classification of Prokaryotic and Eukaryotic Sir2-like ProteinsBiochemical and Biophysical Research Communications, 2000
- The language of covalent histone modificationsNature, 2000
- Characterization of Five Human cDNAs with Homology to the Yeast SIR2 Gene: Sir2-like Proteins (Sirtuins) Metabolize NAD and May Have Protein ADP-Ribosyltransferase ActivityBiochemical and Biophysical Research Communications, 1999
- Effects of Cell Density and Trichostatin A on the Expression ofHDAC1andp57Kip2in Hep 3B CellsBiochemical and Biophysical Research Communications, 1998
- Expression of the liver‐enriched transcription factors C/EBPα, C/EBPβ, HNF‐1, and HNF‐4 in preneoplastic nodules and hepatocellular carcinoma in rat liverMolecular Carcinogenesis, 1995
- Histone deacetylaseFEBS Letters, 1993
- Ultraviolet light-induced DNA repair synthesis in hepatocytes from species of differing longevitiesMechanisms of Ageing and Development, 1985